CLINICAL TRIALS- SHARED RESOURCES

临床试验-共享资源

基本信息

  • 批准号:
    7944908
  • 负责人:
  • 金额:
    $ 7.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-07 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

The Winship Cancer Institute's Clinical Trials Shared Resource, referred to as the Clinical Trials Office (WCI CTO), is part of the overall support for clinical trials research in the WCI and its activities are coordinated with the Protocol Review and Monitoring System (PRMS) and Data Safety Monitoring Plan (DSMP). The overall goal of the WCI CTO is to advance progress in cancer care through the support of highquality, high-impact clinical research by Cancer Institute members. In our organizational mode diseasefocused physician investigators work directly with research nurses, coordinators and regulatory specialists organized into nine disease or site-based management teams called Working Groups. The staff in the Working Group assist clinical investigators in enrolling subjects on therapeutic clinical research protocols and are responsible for high-quality data collection and submission. The Working Groups encompass all clinical investigators and clinical trial activities conducted at Emory University and its clinical affiliates. These activities are supported and coordinated by a central administrative core that provides oversight of clinical trial prioritization; budget and finances; staff training; development and implementation of policies and procedures for clinical trials activation, accrual, management, and operations; quality assurance and auditing functions; and regulatory affairs. The WCI CTO also provides support for designing investigator-initiated institutional trials in coordination with the Biostatistics Shared Core Resource. The WCI CTO works closely with the School of Medicine's clinical trials office as related to regulatory compliance and budgets and with the University's Office of Sponsored Programs for contracting issues. The WCI CTO supports therapeutic, prevention, ancillary, correlative, and non-interventional studies for investigators representing all four WCI scientific program areas. Under the direction of the Medical Director, Edmund Waller, MD, PhD, and the Associate Directors, Stephanie McMillan, RN, and Carol Hill, RN (Clinical Affairs), and Leah Holloway (Regulatory Affairs), the WCI CTO maintains a centralized database for both adult and pediatric trials and oversees all the services and functions of the CTO and its staff. In 2007, 442 unique cancer patients were accrued to therapeutic clinical trials representing 12% of the number of reportable cancer patients newly seen in that year. The number of patients enrolled on therapeutic clinical trails and has tripled over the past 6 years, with the fastest growth rates in the past 3 years seen in therapeutic institutional studies. Expanded access to clinical research and continued accrual of cancer patients onto therapeutic institutional studies are central to achieving the mission of the Winship Cancer Institute.
Winship癌症研究所的临床试验共享资源,简称临床试验办公室(WCI CTO),是WCI临床试验研究整体支持的一部分,其活动与方案审查和监测系统(PRMS)和数据安全监测计划(DSMP)协调。WCI CTO的总体目标是通过支持癌症研究所成员的高质量,高影响力的临床研究来推动癌症治疗的进展。在我们的组织模式中,以疾病为重点的医生研究人员直接与研究护士,协调员和监管专家合作,组织成九个疾病或基于站点的管理团队,称为工作组。工作组的工作人员协助临床研究者按照治疗性临床研究方案招募受试者,并负责高质量的数据收集和提交。工作组涵盖所有临床 埃默里大学及其临床附属机构开展的研究者和临床试验活动。这些 活动由一个中央行政核心支持和协调,该核心负责监督临床试验的优先顺序;预算和财务;工作人员培训;制定和实施临床试验启动、应计、管理和运营的政策和程序;质量保证和审计职能;以及监管事务。WCI CTO还与生物统计学共享核心资源协调,为设计制药商发起的机构试验提供支持。WCI CTO与医学院的临床试验办公室密切合作,涉及监管合规和预算,并与大学的赞助项目办公室合作解决合同问题。WCI CTO支持代表所有四个WCI科学项目领域的研究者进行治疗性、预防性、辅助性、相关性和非干预性研究。在医学总监Edmund Waller(医学博士、哲学博士)和副总监Stephanie McMillan(注册护士)、Carol Hill(注册护士)(临床事务)和Leah霍洛威(法规事务)的指导下,WCI CTO维护一个用于成人和儿科试验的集中数据库,并监督CTO及其工作人员的所有服务和职能。2007年,442名独特的癌症患者参加了治疗性临床试验,占当年新发现的可报告癌症患者数量的12%。参加治疗性临床试验的患者数量在过去6年中增加了两倍,其中过去3年的最快增长率见于治疗性机构研究。扩大获得临床研究和癌症患者的治疗机构研究的持续积累是实现温希普癌症研究所的使命的核心。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edmund K Waller其他文献

Irradiated Donor Lymphocyte Infusion, A Novel Approach To Prevent Graft Failure During Allogeneic Bone Marrow Transplant • 797
辐照供者淋巴细胞输注:预防同种异体骨髓移植期间移植物衰竭的新方法•797
  • DOI:
    10.1203/00006450-199804001-00818
  • 发表时间:
    1998-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Alan M Ship;Richard Carter;Timothy Murray;Anastasia Gurriero;Edmund K Waller
  • 通讯作者:
    Edmund K Waller

Edmund K Waller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edmund K Waller', 18)}}的其他基金

Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体树突状细胞优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    10402871
  • 财政年份:
    2020
  • 资助金额:
    $ 7.07万
  • 项目类别:
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体树突状细胞优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    10052895
  • 财政年份:
    2020
  • 资助金额:
    $ 7.07万
  • 项目类别:
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体树突状细胞优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    10645013
  • 财政年份:
    2020
  • 资助金额:
    $ 7.07万
  • 项目类别:
Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体树突状细胞优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    9893083
  • 财政年份:
    2019
  • 资助金额:
    $ 7.07万
  • 项目类别:
Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation
制造病原体灭活血小板裂解物来治疗角膜炎症
  • 批准号:
    9048135
  • 财政年份:
    2015
  • 资助金额:
    $ 7.07万
  • 项目类别:
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体 pDC 优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    9234506
  • 财政年份:
    2014
  • 资助金额:
    $ 7.07万
  • 项目类别:
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体 pDC 优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    8837590
  • 财政年份:
    2014
  • 资助金额:
    $ 7.07万
  • 项目类别:
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation
使用供体 pDC 优化同种异体干细胞移植中的 GvHD 和 GvL
  • 批准号:
    8630742
  • 财政年份:
    2014
  • 资助金额:
    $ 7.07万
  • 项目类别:
Modified Donor Lymphocytes Infusion (mDLI) for Rapid Immune Reconstitution
用于快速免疫重建的改良供体淋巴细胞输注 (mDLI)
  • 批准号:
    8342005
  • 财政年份:
    2008
  • 资助金额:
    $ 7.07万
  • 项目类别:
Project 3: Red cell transfusions and donor T-cell activation in allo-stem cell t
项目 3:同种异体干细胞中的红细胞输注和供体 T 细胞激活
  • 批准号:
    9100838
  • 财政年份:
    2008
  • 资助金额:
    $ 7.07万
  • 项目类别:

相似海外基金

Structural Racism, Pharmacy Closures and Disparities in Medication Adherence Among Older Adult Medicare Part-D Beneficiaries
结构性种族主义、药房关闭以及老年人医疗保险 D 部分受益人的药物依从性差异
  • 批准号:
    10568717
  • 财政年份:
    2023
  • 资助金额:
    $ 7.07万
  • 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
  • 批准号:
    10419967
  • 财政年份:
    2022
  • 资助金额:
    $ 7.07万
  • 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
  • 批准号:
    10592441
  • 财政年份:
    2022
  • 资助金额:
    $ 7.07万
  • 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
  • 批准号:
    10369750
  • 财政年份:
    2021
  • 资助金额:
    $ 7.07万
  • 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
  • 批准号:
    10633248
  • 财政年份:
    2021
  • 资助金额:
    $ 7.07万
  • 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
  • 批准号:
    10487516
  • 财政年份:
    2021
  • 资助金额:
    $ 7.07万
  • 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
  • 批准号:
    10228564
  • 财政年份:
    2018
  • 资助金额:
    $ 7.07万
  • 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
  • 批准号:
    9347041
  • 财政年份:
    2017
  • 资助金额:
    $ 7.07万
  • 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
  • 批准号:
    9480702
  • 财政年份:
    2016
  • 资助金额:
    $ 7.07万
  • 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
  • 批准号:
    9906853
  • 财政年份:
    2016
  • 资助金额:
    $ 7.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了